Similar articles

• Pathophysiology of levodopa-induced dyskinesia: potential for new therapies.

  Bezard E, Brotchie JM, Gross CE. Bezard E, et al. Nat Rev Neurosci. 2001 Aug;2(8):577-88. doi: 10.1038/35086062. Nat Rev Neurosci. 2001. PMID: 11484001 Review.
• L-DOPA-induced dyskinesia: cellular mechanisms and approaches to treatment.

  Cenci MA. Cenci MA. Parkinsonism Relat Disord. 2007;13 Suppl 3:S263-7. doi: 10.1016/S1353-8020(08)70014-2. Parkinsonism Relat Disord. 2007. PMID: 18267248 Review.
• Levodopa-induced dyskinesias in Parkinson's disease: etiology, impact on quality of life, and treatments.

  Encarnacion EV, Hauser RA. Encarnacion EV, et al. Eur Neurol. 2008;60(2):57-66. doi: 10.1159/000131893. Epub 2008 May 15. Eur Neurol. 2008. PMID: 18480609 Review.
• [Management of levodopa-induced dyskinesia].

  Rascol O, Ferreira JJ, Payoux P, Brefel-Courbon Ch, Montastruc JL. Rascol O, et al. Rev Neurol (Paris). 2002 Dec;158 Spec no 1:S117-24. Rev Neurol (Paris). 2002. PMID: 12690671 Review. French.
• Levodopa-induced dyskinesias in autopsy-proven cortical-basal ganglionic degeneration.

  Frucht S, Fahn S, Chin S, Dhawan V, Eidelberg D. Frucht S, et al. Mov Disord. 2000 Mar;15(2):340-3. doi: 10.1002/1531-8257(200003)15:2<340::aid-mds1025>3.0.co;2-o. Mov Disord. 2000. PMID: 10752591 No abstract available.